Press coverage about Repligen (NASDAQ:RGEN) has been trending somewhat positive on Sunday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repligen earned a news impact score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.4736769787516 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

RGEN has been the subject of several research analyst reports. Citigroup initiated coverage on Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 price objective for the company. CL King initiated coverage on Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price objective for the company. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday, October 5th. JPMorgan Chase & Co. initiated coverage on Repligen in a report on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Jefferies Group reiterated a “hold” rating and issued a $40.00 price objective on shares of Repligen in a report on Thursday, October 19th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $44.38.

Shares of Repligen (NASDAQ RGEN) opened at $36.61 on Friday. Repligen has a fifty-two week low of $28.48 and a fifty-two week high of $46.81. The firm has a market capitalization of $1,594.91, a P/E ratio of 62.05, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter last year, the business posted $0.08 EPS. The business’s revenue was up 48.2% on a year-over-year basis. analysts expect that Repligen will post 0.61 earnings per share for the current year.

In other news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the completion of the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Repligen (RGEN) Share Price” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.